Postpartum Depression Drug Market Estimated to Witness High Growth Owing to Increasing Global Awareness

Postpartum depression drugs target symptoms such as lack of concentration, mood swings, irritability among breastfeeding mothers and new mothers. Postpartum depression is one of the most common complications during childbirth. This disorder can be treated using antidepressants, psychotherapies, and other forms of counseling. The global postpartum depression drug market is estimated to be valued at US$ 6.65 Bn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

One of the key drivers of growth in the global postpartum depression drug market is increasing global awareness about maternal mental health issues. According to studies, 10-15% of new mothers suffer from postpartum depression globally. However, only 20% of affected women in developing countries receive treatment due to lack of screening and diagnosis. Several government and non-government organizations are focusing on creating awareness on maternal mental health issues and available treatment options. For instance, Postpartum Support International (PSI) conducts digital campaigns and webinars to educate new mothers and healthcare professionals on identifying symptoms of postpartum mood disorders.

Antidepressants are widely prescribed for treating postpartum depression as they help balance brain chemicals like serotonin and norepinephrine. Selective serotonin reuptake inhibitors (SSRIs) are preferred for postpartum depression treatment due to their efficacy and safety for breastfeeding infants. Popular SSRI drugs for postpartum depression include citalopram, sertraline, and fluoxetine. Increasing awareness is driving more women to seek treatments such as counseling and antidepressants therapy, thereby fueling growth of the postpartum depression drug market.

SWOT Analysis

Strength: Postpartum depression drug market has a large patient population suffering from postpartum depression. Rising awareness among new mothers about the condition and availability of treatment options is driving the market growth. Drug manufacturers are investing extensively in R&D of innovative drugs and formulations with higher efficacy and fewer side effects.

Weakness: Postpartum depression often goes undiagnosed as the symptoms are sometimes mistaken as normal adjustment issues after childbirth. Lack of access to mental healthcare in developing countries is also a weakness. High costs of branded drugs can limit their adoption in low and middle-income nations.

Opportunity: Growing mental health concerns and increasing focus on women’s healthcare post childbirth present lucrative opportunities. Emergence of generics provides affordable treatment options in developing regions. Rising online drug retailers also provide opportunities to reach out to more patients.

Threats: Patent expiries of blockbuster drugs result in increased competition from generics. Stringent regulations for psychiatric drug approvals can delay market entry of new formulations. Non-compliance to treatment due to social stigma associated with the condition can hamper market growth.

Key Takeaways

The Global Postpartum Depression Drug Market is expected to witness high growth over the forecast period of 2023 to 2030 driven by rising awareness and diagnosis rates. The market size is estimated to increase from US$ 6.65 Bn in 2023 to over US$ 7 Bn by 2030, registering a CAGR of around 3.0%.

Regional analysis

North America currently dominates the global market owing to developed healthcare infrastructure and supportive reimbursement policies. However, Asia Pacific region is expected to grow at the fastest pace during the forecast period. Countries like China, Japan and India are witnessing increasing prevalence of postpartum depression and growing adoption of antidepressants.

Key players

Key players operating in the postpartum depression drug market are Sun Pharma, UCB Farchim SA, Yangtze River Pharmaceutical (Group) Co., Ltd., Livzon Pharmaceutical Group Inc., Nanjing Sanhome Pharmaceutical Co.,Ltd., PKU Healthcare Corp., Ltd., Qilu Pharmaceutical Co., Ltd., Jilin Huakang Pharmaceutical Co., Ltd., Sichuan Hengrui Pharmaceutical Co., Ltd., Shaixi Taiyuan Pharmaceutical Co., Ltd., Guangdong Guoyuan Sinopharm Co., Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Zhejiang Zhebei Pharmaceutical Co., Ltd., Nanjing Chang’ao Pharmaceutical Co., Ltd., Xinhua Pharmaceutical (Gaomi) Co., Ltd.

Get more insights on this topic: https://www.pressreleasebulletin.com/postpartum-depression-drug-market-demand-and-overview/